Ecallantide (Dyax/Genzyme)
Lehmann, A.
Current Opinion in Investigational Drugs 7(3): 282-290
2006
ISSN/ISBN: 1472-4472 PMID: 16555689 Document Number: 603420
Ecallantide is one of a series of small-protein kallikrein inhibitors, identified through Dyax Corp's phage display technology, that is being developed by Dyax and Genzyme as a potential subcutaneous treatment for hereditary angioedema (HAE). Dyax is also independently developing ecallantide for the reduction of peri-operative blood loss during cardiopulmonary bypass surgery. The company had expected to begin phase II clinical studies in coronary bypass graft patients in the first half of 2005; however, by October 2005, these trials had been delayed until partnership negotiations for the program were completed. A pivotal, phase III clinical trial of ecallantide in HAE began in December 2005.